Literature DB >> 3578812

Preparation of phosphorylcholine derivatives of bovine serum albumin and their application to the affinity chromatography of C-reactive protein.

N L Stults, Y C Lee, C A Hoppe, K Kawaguchi, S Kohda, I Takagahara, T Koishi, T Y Liu.   

Abstract

A simple method for the preparation of phosphorylcholine derivatives of bovine serum albumin (PC-BSA) by reductive alkylation of the amino groups of bovine serum albumin with choline phosphoryl glycoaldehyde is described. Choline phosphoryl glycoaldehyde was generated by periodate oxidation of glyceryl phosphorylcholine. PC-BSA was immobilized on SH-derivatized Toyopearl HW 65 by reacting the single SH group of PC-BSA with a bismaleimido reagent and then coupling maleimidated PC-BSA to the thiolated gel. The affinity purification of C-reactive protein (CRP), which is based on the Ca2+-dependent affinity of CRP for the phosphorylcholine residue of PC-BSA, was readily accomplished using the PC-BSA Toyopearl HW 65 column. The resulting CRP preparation from serum and pleural fluid was homogeneous as assessed by native polyacrylamide gel electrophoresis. PC-BSA derivatives were also shown to be reactive with Limulus polyphemus CRP.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3578812     DOI: 10.1016/0003-2697(87)90490-8

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  2 in total

1.  Carbohydrate ligands of human C-reactive protein: binding of neoglycoproteins containing galactose-6-phosphate and galactose-terminated disaccharide.

Authors:  Reiko T Lee; Yuan C Lee
Journal:  Glycoconj J       Date:  2006-07       Impact factor: 2.916

2.  Zwitterionic Phosphodiester-Substituted Neoglycoconjugates as Ligands for Antibodies and Acute Phase Proteins.

Authors:  Karell Pérez Labrada; Sebastian Strobl; Barbara Eckmair; Markus Blaukopf; Zuzanna Dutkiewicz; Alba Hykollari; Daniel Malzl; Katharina Paschinger; Shi Yan; Iain B H Wilson; Paul Kosma
Journal:  ACS Chem Biol       Date:  2020-01-29       Impact factor: 5.100

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.